A guardian molecule ensures that liver cells do not lose their identity. The discovery is of great interest for cancer medicine because a change of identity of cells has come into focus as a ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...

A man living with advanced liver cancer has seen his tumour shrink by over half as “exciting” new clinical trials are ...

Being thrown into this situation is hard because they are separate and they know that... and when they see each other it ...

The WHO’s cancer agency’s designation for hairstylists does not extend to people who dye their hair. That remains “not ...

The World Health Organisation (WHO) is calling for cigarette-style warnings on alcohol to raise awareness about the link between drinking and cancer. Alcohol causes 800,000 deaths across Europe each ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Get Instant Summarized Text (Gist) The CLEAR study highlights the importance of tumor size reduction in enhancing survival outcomes for advanced renal cell carcinoma (aRCC) patients. The ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue ...